Pharmaceutical composition, methods for treating and uses thereof
Uli Christian Broedl, Mainz (DE); Odd-Erik Johansen, Hoevik (NO); Gabriel Woojai Kim, Mainz am Rhein (DE); Eric Williams Mayoux, Neauphle-le-Vieux (FR); Afshin Salsali, Princeton, NJ (US); Nima Soleymanlou, Maple (CA); Maximilian von Eynatten, Wiesbaden (DE); Hans-Juergen Woerle, Grandvaux VD (CH); David Z. I. Cherney, Toronto (CA); Bruce A. Perkins, Toronto (CA); Andreas Daiber, Scheessel (DE); and Thomas Muenzel, Mainz (DE)
Assigned to Boehringer Ingelheim International GmbH, Ingelheim am Rhein (DE)
Filed by Boehringer Ingelheim International GmbH, Ingelheim am Rhein (DE)
Filed on Jul. 21, 2021, as Appl. No. 17/381,488.
Application 17/381,488 is a continuation of application No. 16/796,085, filed on Feb. 20, 2020, abandoned.
Application 16/796,085 is a continuation of application No. 15/918,477, filed on Mar. 12, 2018, abandoned.
Application 15/918,477 is a continuation of application No. 14/918,713, filed on Oct. 21, 2015, granted, now 9,949,997, issued on Apr. 24, 2018.
Application 14/918,713 is a continuation of application No. 14/244,196, filed on Apr. 3, 2014, abandoned.
Claims priority of provisional application 61/942,301, filed on Feb. 20, 2014.
Claims priority of provisional application 61/835,811, filed on Jun. 17, 2013.
Claims priority of provisional application 61/835,809, filed on Jun. 17, 2013.
Claims priority of provisional application 61/823,041, filed on May 14, 2013.
Claims priority of provisional application 61/808,807, filed on Apr. 5, 2013.
Prior Publication US 2021/0346418 A1, Nov. 11, 2021
1. A method for reducing the risk of heart failure or hospitalization for heart failure in a patient with a previous or existing myocardial infarction, the method comprising administering a therapeutically effective amount of empagliflozin to the patient.